Popular Articles

No Time For Complacency In Pandemic Planning: Aon
In light of the World Health Organization raising its pandemic flu alert to the top phase of its six-phase scale, Aon Corporation (NYSE: AOC) today issued the following statement by Gisele Norris, DrPH, national director of Aon Healthcare"s alternative risk practice:
diet pills Prezzi dentisti croazia
CorNova(R) Receives CE Mark Approval For Valecor Platinum(R) Coronary Stent System
CorNova Inc. announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System.
News of the day
Opinion Pieces Discuss Whether Current Efforts To Fix Health Costs Will Produce Sufficient Savings
David Brooks, New York Times: Health care costs have become "the crucial issue of [President Obama"s] whole presidency," Times columnist Brooks writes. According to Brooks, Obama"s original plan was to fund his priorities, including education and energy, with debt that would be paid off with future savings resulting from health care reform. Brooks writes that Obama"s aides have been discussing "game-changers" -- such as health information technology, wellness programs, preventive medicine, comparative effective measures and altering reimbursement policies -- that would result in cost reductions. However, Brooks writes that most experts do not think such efforts would "produce much in the way of cost savings over the next 10 years" and that "nobody is sure" the efforts would "ever produce significant savings." Brooks writes that because "there are deep structural forces, both in Medicare and the private insurance market" that make it "nearly impossible to put together a majority coalition for a bill" challenging those structures, reform efforts this year likely will produce a "medium-size bill that expands coverage to some groups but does relatively little to control costs." Brooks concludes, "Without serious health cost cuts," Obama"s agenda "will hasten fiscal suicide" (Brooks, New York Times, 5/15).
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):